Evidence map›Paper›PMID 22260183›Full record

ArticleJournal of cellular and molecular medicine2012

Amniotic membrane-derived cells inhibit proliferation of cancer cell lines by inducing cell cycle arrest.

Marta Magatti, Silvia De Munari, Elsa Vertua, Ornella Parolini

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05363644 (Treatment Protocol With BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy), which is not on this map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05363644 phase3withdrawnnot on this mapstarted 2023, after this paper: background citation

Treatment Protocol With BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy: A Prospective Open Label Single-Center Study

TypeinterventionalSponsorAdventHealthRan2023 to 2024Enrolled0ConditionsProstate Cancer, Prostatectomy, Erectile Dysfunction Following Radical Prostatectomy, Incontinence, UrinaryArmsBioDFence G3
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Preparation of Dried Amniotic Membrane for Corneal Repair.Methods in molecular biology (Clifton, N.J.) · 2020
    Article
  16. Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives.Advances in experimental medicine and biology · 2020
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Marta MagattiCentro di Ricerca E. Menni, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
Silvia De Munari
Elsa Vertua
Ornella Parolini
Fondazione Poliambulanza Istituto Ospedaliero · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cells derived from the amniotic foetal membrane of human term placenta have drawn particular attention mainly for their plasticity and immunological properties, which render them interesting for stem-cell research and cell-based therapeutic applications. In particular, we have previously demonstrated that amniotic mesenchymal tissue cells (AMTC) inhibit lymphocyte proliferation in vitro and suppress the generation and maturation of monocyte-derived dendritic cells. Here, we show that AMTC also significantly reduce the proliferation of cancer cell lines of haematopoietic and non-haematopoietic origin, in both cell-cell contact and transwell co-cultures, therefore suggesting the involvement of yet-unknown inhibitory soluble factor(s) in this 'cell growth restraint'. Importantly, we provide evidence that the anti-proliferative effect of AMTC is associated with induction of cell cycle arrest in G0/G1 phase. Gene expression analyses demonstrate that AMTC can down-regulate cancer cells' mRNA expression of genes associated with cell cycle progression, such as cyclins (cyclin D2, cyclin E1, cyclin H) and cyclin-dependent kinase (CDK4, CDK6 and CDK2), whilst they up-regulate cell cycle negative regulator such as p15 and p21, consistent with a block in G0/G1 phase with no progression to S phase. Taken together, these findings warrant further studies to investigate the applicability of these cells for controlling cancer cell proliferation in vivo.

Indexed as

AmnionCell Cycle CheckpointsCell DivisionCell Line, TumorCell ProliferationCoculture TechniquesCyclin D2Cyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p21Cyclin ECyclin HDown-RegulationG1 PhaseCCND2 protein, humanCCNE1 protein, humanCDK2 protein, humanCDK4 protein, humanCDK6 protein, humanCyclin D2Cyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p21Cyclin ECyclin HOncogene ProteinsRNA, Messenger

Identifiers

PMID22260183
PMCPMC3822990
OpenAlexW2149170603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.